Extension to Engagement Agreement

Exhibit 1.3

Execution Version

January [__], 2025

STRICTLY CONFIDENTIAL

60 Degrees Pharmaceuticals, Inc.

1025 Connecticut Avenue NW, Suite 1000,

Washington, D.C. 20036

Attn: Geoffrey Dow, Chief Executive Officer and President

Dear Mr. Dow:

Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of August 30, 2024, as amended on September 3, 2024, by and between 60 Degrees Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement.

The parties agree to amend the Engagement Agreement (this “Amendment”), as evidenced by their signatures hereon, on the terms set forth herein as follows:

The parties acknowledge and agree that the Term of the Engagement Agreement shall extend from its expiration date for an additional (90) days.

Except as expressly set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the execution of this Amendment and shall not be in any way changed, modified or superseded except as set forth herein. Notwithstanding anything to the contrary contained herein, this Amendment shall be subject to the provisions regarding governing law and miscellaneous provisions set forth in Paragraphs I and M of the Engagement Agreement, and such provisions are incorporated herein by this reference, mutatis mutandis.

[Remainder of page intentionally left blank]

430 Park Avenue | New York, New York 10022 | 212 ###-###-#### | www.hcwco.com

Member: FINRA/SIPC

In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this Amendment shall constitute a binding agreement as of the date indicated above.